Category Archives: Cell Biology

Cell Biology

Who’s to Die and Who’s to Live: Mechanical Cue Is at the Origin of Cell Death Decision – SciTechDaily

In many species including humans, the cells responsible for reproduction, the germ cells, are often highly interconnected and share their cytoplasm. In the hermaphrodite nematode Caenorhabditis elegans, up to 500 germ cells are connected to each other in the gonad, the tissue that produces eggs and sperm. These cells are arranged around a central cytoplasmic corridor and exchange cytoplasmic material fostering cell growth, and ultimately produce oocytes ready to be fertilized.

In past studies, researchers have found that C. elegans gonads generate more germ cells than needed and that only half of them grow to become oocytes, while the rest shrinks and die by physiological apoptosis, a programmed cell death that occurs in multicellular organisms. Now, scientists from the Biotechnology Center of the TU Dresden (BIOTEC), the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), the Cluster of Excellence Physics of Life (PoL) at the TU Dresden, the Max Planck Institute for the Physics of Complex Systems (MPI-PKS), the Flatiron Institute, NY, and the University of California, Berkeley, found evidence to answer the question of what triggers this cell fate decision between life and death in the germline.

Hydraulic instabilities dictate the volumes of germ cells and balloons Left: Picture of two balloons connected through a central tube, any new air coming through the white pipe will inflate the red balloon rather than the blue one. Right: Spinning-disk confocal image of interconnected C. elegans germ cells. Cortical actin showing the cell cortex is labelled in magenta and myosin, delineating the germ cells openings through which both cells exchange cytoplasmic material, is labelled in green. Credit: TU Dresden

Prior studies revealed the genetic basis and biochemical signals that drive physiological cell death, but the mechanisms that select and initiate apoptosis in individual germ cells remained unclear. As germ cells mature along the gonad of the nematode, they first collectively grow in size and in volume homogenously. In the study just published in Nature Physics, the scientists show that this homogenous growth suddenly shifts to a heterogenous growth where some cells become bigger and some cells become smaller.

The researcher Nicolas Chartier in the group of Stephan Grill, and co-first author of the study, explains: By precisely analyzing germ cell volumes and cytoplasmic material fluxes in living worms and by developing theoretical modeling, we have identified a hydraulic instability that amplifies small initial random volume differences, which causes some germ cells to increase in volume at the expense of the others that shrink. It is a phenomenon, which can be compared to the two-balloon instability, well known of physicists. Such an instability arises when simultaneously blowing into two rubber balloons attempting to inflate them both. Only the larger balloon will inflate, because it has a lower internal pressure than the smaller one, and is therefore easier to inflate.

This is what is at play in the selection of germ cells: such pressure differences tend to destabilize the symmetric configuration with equal germ cell volumes, so-called hydraulic instabilities, leading to the growth of the larger germ cell at the expense of the smaller one. By artificially reducing germ cell volumes via thermoviscous pumping (FLUCS method: focused-light-induced cytoplasmic streaming), the team demonstrated that the reduction in cell volumes leads to their extrusion and cell death, indicating that once a cell is below a critical size, apoptosis is induced and the cell dies.

By using confocal imaging, the researchers could image the full organism of the living worm to receive a global and precise picture of the volumes of all the gonad cells, as well as the exchange of fluids between the cells. Stephan Grill, Speaker of the Cluster of Excellence Physics of Life (PoL) and supervisor of the multidisciplinary work, adds These findings are very exciting because they reveal that the life and death decision in the cells is of mechanical nature and related to tissue hydraulics. It helps to understand how the organism auto-selects a cell that will become an egg. Furthermore, the study is another example of the excellent cooperation between biologists, physicists and mathematicians in Dresden.

Reference: A hydraulic instability drives the cell death decision in the nematode germline by Nicolas T. Chartier, Arghyadip Mukherjee, Julia Pfanzelter, Sebastian Frthauer, Ben T. Larson, Anatol W. Fritsch, Rana Amini, Moritz Kreysing, Frank Jlicher and Stephan W. Grill, 20 May 2021, Nature Physics.DOI: 10.1038/s41567-021-01235-x

Read more:
Who's to Die and Who's to Live: Mechanical Cue Is at the Origin of Cell Death Decision - SciTechDaily

Cell Biology

Bruker Launches timsTOF trueSCP for Unbiased Single Cell 4D-Proteomics and Next-gen timsTOF Pro 2 with Unprecedented Proteomic Depth – Business Wire

BILLERICA, Mass.--(BUSINESS WIRE)--At Brukers virtual 4D-Proteomics eXceed Symposium (eXceed Symposia 2021 | Bruker), Bruker Corporation (Nasdaq: BRKR) today announced the launch of two new timsTOF instruments. They further advance and enable new applications and methods in unbiased proteomics, epiproteomics/PTM characterization, and unbiased, deep multiomic biomarker discovery, for example in cancer liquid biopsy research. Brukers collaborators are making major progress in unbiased single cell proteomics, phosphoproteomics and plasma proteomics, leveraging the speed, sensitivity and dynamic range of large-scale CCS-enabled 4D-Proteomics and 4D-Epiproteomics.

At the end of 2020, a breakthrough paper by the Mann-group demonstrated unbiased, true single-cell proteomics on over 1,400 protein groups on a timsTOF R&D prototype to address new quantitative questions in single-cell biology and pathobiology.1 Bruker has accelerated its product development and today launches the ultra-high sensitivity timsTOF trueSCP system for unbiased, quantitative single-cell 4D-Proteomics, and for ultra-sensitive neoantigen discovery in immunopeptidomics.

Since its introduction in 2017, the timsTOF Pro system has offered researchers new capabilities in unbiased CCS-enabled 4D-Proteomics, typically on 5x-20x lower sample amounts and with 3x-5x faster run times for single shot, deep proteomics - with higher throughput and unprecedented robustness.

With the introduction of the next-generation timsTOF Pro 2, Bruker continues the revolution in CCS-enabled 4D-Proteomics, as well as in 4D-Epiproteomics, defined here broadly as the characterization of all protein posttranslational modifications (PTMs). The timsTOF Pro 2 offers deeper proteome coverage of >6,000 protein groups and >60,000 unique peptides in 60 minute gradients on 200 ng HeLa digests. It also achieves good depth of proteome and epiproteome coverage at 10x lower amounts, e.g., with ~4,000 proteins and ~30,000 peptides on 20 ng digests. The outstanding timsTOF Pro 2 sensitivity significantly enhances methods to detect post-translational modificiations (PTMs), such as phosphoproteomics and ubiquitination studies, for CCS-enabled, unbiased, large-scale 4D-Epiproteomics, which is tremendously important in physiology, cell biology and disease biology, especially in cancer.

Bruker also announced new capabilities in PaSER real-time search software for 4D-Proteomics. The new PaSER 2022 offers large-scale CCS-enabled bioinformatics, leveraging the unique tims/PASEF methods. For example, the new TIMScore increases the confidence of peptide IDs by leveraging the fourth dimension of large-scale collision cross sections (CCS) on all measured peptides. Increased confidence using CCS reduces ambiguities of redundant peptide sequences - resulting in more protein group and unique peptide identifications based on the same FDR threshold.

Frank H. Laukien, Bruker President and CEO, commented: I believe that the timsTOF trueSCP is a revolutionary new tool for unbiased, deep and quantitative single-cell biology that is complementary to scRNA-seq. In the future, basic research in single-cell biology and pathogenesis will greatly benefit from having both eyes open in gene expression, by combining transcriptomics with unbiased, deep and quantitative proteomics and epiproteomics data for multiomic biomarker panels.

Dr. Laukien continued: In liquid biopsies there is an unmet clinical need for greater cancer stage I/II detection sensitivity and improved positive predictive values, as well as for earlier detection of therapy resistance. For integrated multiomic deep learning in both, cancer cell genomics and epiproteomics, as well as in host immune response and tumor microenvironment, unbiased proteomics and PTMs are highly complementary to NGS for achieving further major progress in PPV for the benefit of patients.

A. timsTOF trueSCP Launch

The timsTOF trueSCP is the culmination of a collaboration with the laboratory of Professor Matthias Mann at the Max Planck Institute of Biochemistry in Martinsried, Germany, and with Evosep on new Whisper methods at ultra-low flow rates of ~100 nL/min.

The timsTOF trueSCP achieves 5 times higher ion transmission for data-independent dia-PASEF, or parallel reaction monitoring prm-PASEF methods. The dia-PASEF 2 method has demonstrated true, unbiased 4D-Proteomics from single cells 1 with quantitation of ~1,500 proteins/cell, in hundreds of isolated single cells ex situ, in combination with the Evosep One LC with Whisper. The timsTOF trueSCP is a dedicated ultra-high sensitivity instrument for unbiased single cell proteomics, after laser capture microdissection of one or a few cells, as well as for ultra-sensitive neoantigen discovery in immunopeptidomics in the field of immunooncology research. With the timsTOF trueSCP, a system is now available to expand the single-cell biology horizons beyond genomics and transcriptomics to unbiased, quantitative 4D-Proteomics.

Quantitative biology can now be done also with unbiased single cell proteomics, as cells at different stages in the growth cycle have a protein core with sufficient copy numbers to observe statistically relevant changes in abundance, when compared to sparse mRNA copy numbers.

Professor Matthias Mann commented: I always said that single cell proteomics would not happen in my lifetime, but Im happy to have been proven wrong. Single-cell technologies are revolutionizing biology but are today mainly limited to imaging and deep sequencing. However, proteins are the main drivers of cellular function and in-depth characterization of individual cells by mass spectrometry (MS)-based proteomics using instrumentation like the timsTOF trueSCP will be highly complementary. Our laboratory has been very pleased with the collaboration with Bruker, and I congratulate the Bruker team on the rapid commercialization of the novel timsTOF trueSCP technology.

B. Next-generation timsTOF Pro 2 Launch

The timsTOF Pro 2 is the new proteomics workhorse for robust, unbiased, deep and quantitative 4D-Proteomics and 4D-Epiproteomics for plasma, tissue samples and from cell cultures. Further design advances combined with enhanced dda-PASEF, dia-PASEF and prm-PASEF methods deliver industry-leading performance, with unparalleled robustness and throughput. The timsTOF Pro 2 allows the detection of > 6,000 proteins and > 60,000 peptides by dda-PASEF with 60 minute gradients on 200 ng of digest. It also has new high sensitivity methods that enable very good proteome coverage with 10x less digest, down to 20 ng, for >3,500 protein groups and >25,000 unique peptides using a 30 minute gradient. dia-PASEF workflows on timsTOF Pro 2 include an improved interface for designing experiments, and can now identify ~8,000 protein groups and 70,000 peptides in 60 minutes on 200 ng of digests.

These timsTOF Pro 2 performance improvements are important for 4D-Epiproteomics, and particularly phosphoproteomics. Phosphorylation is key to signaling and is often mis-regulated in cancer and other diseases. Phosphopeptides are enriched prior to analysis, and researchers often started with several milligrams of biological material to isolate a sufficient quantity of phosphopeptides for analysis. As shown by Professor Stefan Tenzer at the Institute for Immunology of the University Medical Center of the Johannes-Gutenberg University Mainz, with the timsTOF Pro 2 it is now possible to start from just 150 ug of protein and identify 27,768 unique phosphopeptides. In particular, 457 co-eluting positional phosphorylation isomers were resolved by the combination of TIMS and PASEF. Even with 25 ug of protein, >4,400 phosphopeptides can be reproducibly identified, paving the way toward phosphoproteomics on needle biopsies.

Professor Tenzer stated: Besides its high sensitivity, a unique aspect of the TIMS technology is its capability to resolve positional phosphorylation isomers in the gas phase by ion mobility, thus providing more detailed insights into signaling pathways.

Sensitivity is absolutely crucial in immunopeptidomics, and Professor Janne Lehti of the Science for Life Laboratory, Department of Oncology-Pathology at the Karolinska Institute in Stockholm, Sweden, added: We have been impressed with the performance of the timsTOF Pro. In particular, the speed and sensitivity of the instrument enable us to see more immunopeptides from limited amounts of starting material, which we expect to be particularly valuable for neoantigen discovery and the development of personalized therapies for cancer immunooncology treatments.

C. New PaSER Capabilities

New functionalities of PaSER 2022 include: MOMA Viewer, real-time de novo peptide sequencing and TIMScore for unbiased 4D-Proteomics, in addition to Run & Done search.

Sebastian Vaca, PhD, Research Scientist in the Carr Lab at the Broad Institute of MIT and Harvard, explained: Real-time results by PaSER on our timsTOF Pro have been a huge time saver. They allows us to develop methods faster, inform on LC and instrument performance, and provide a major gain in the efficiency of proteomics and PTM research.

PaSER now has a MOMA (mobility offset mass aligned) viewer to characterize co-eluting isomeric or isobaric ions by large-scale CCS. The GPU-based search has been extended into immunoproteomics. Working with Professor Tony Purcell and Bioinformatics Solutions Inc., the ability to perform real-time de novo sequence assignment delivers new capabilities for novel neoantigen discovery.

Finally, PaSER 2022 incorporates a new CCS-enabled database search algorithm, called TIMScore, developed together with Professor John Yates, and driven by machine learning. TIMScore becomes the first fundamentally CCS-enabled database search algorithm, increasing the number of protein and peptides identified, while maintaining FDR control and real-time search speeds.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Brukers high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: http://www.bruker.com.

More here:
Bruker Launches timsTOF trueSCP for Unbiased Single Cell 4D-Proteomics and Next-gen timsTOF Pro 2 with Unprecedented Proteomic Depth - Business Wire

Cell Biology

Braintale Appoints Industry Leaders Spyros Artavanis-Tsakonas and Nitza Thomasson to Its Board of Directors – BioSpace

We welcome both Spyros and Nitza as international recognized leaders in their respective fields who will help us expand our strategic vision and grow Braintale internationally as they deeply understand our science-based approach and the entrepreneur journey said Julie Rachline, CEO. We are thrilled to complement our board with such distinguished experts, and we are looking forward to a fruitful collaboration comments Vincent Perlbarg, president.

Professor Spyros Artavanis-Tsakonas, a molecular biologist and developmental geneticist, is Professor Emeritus in the Department of Cell Biology at Harvard Medical School. He is the founding Director of the Developmental and Regenerative Biology Program at Harvard Medical School. He joined the Yale faculty in 1981 in the Department of Biology and in 1989 was concurrently, Professor at the Department of Cell Biology at the Yale School of Medicine and served as the Director of the Biological Sciences Division at Yale. He was a Howard Hughes Medical Institute Investigator from 1987 to 1998 when he left for Harvard, where he was appointed Professor of Cell Biology. In 1999 he was elected Professor at the Collge de France, in Paris, holding the Chair of Biology and Genetics of Development until 2012 when he became Professeur honoraire. He is the Founding Director of the Department of Genetics and Developmental Biology at Institut Curie, Paris, 2007-2009.

From 2012 to March 2017, he served as Chief Scientific Officer and Executive Vice President at Biogen Inc.

He is a fellow of the American Academy of Arts and Sciences, an associate member of EMBO, and a corresponding member of the Academy of Athens and a member of the Cambridge Philosophical Society. He is the co- founder and President of Fondation Sante a charitable organization supporting Biomedical research in Greece and a co-founder of the Biotechnology companies Exelixis, Cellzome and Anadys.

Dr Nitza Thomasson is the co-founder of Gensight Biologics (Gene therapy for ophthalmologic diseases) and BrainEver (Advanced medicinal products to treat neurodegenerative diseases). After a post doc at Northwestern & Rush University (Chicago, USA), she joined the pharma industry to develop medicines for neurologic and psychiatric disorders at Servier. Then she moved to the biotech world, joining Fovea Pharma in 2009, that became Ophthalmology Division of Sanofi. She contributed to the start of Tissium (2014 - Head of Development), while co-founding GenSight Biologics (2013 - Preclinical and CMC Officer), then BrainEver (2015 - Chief Operating Officer). In 2018, Nitza founded NtzConsulting.

Nitza is also Venture Partner at OmnesCapital. She is board member to support innovation and growth in the healthcare company portfolio.

About Braintale Braintale is an innovative company opening a new era in medicine by providing physicians with clinically validated prognostic solutions for the management of brain injured patients through sensitive and reliable measurements of brain white-matter microstructure alterations. Building on more than 15 years in clinical development, Braintales products are developed collaboratively to address medical need and fulfill expectations of healthcare professionals and patients alike.Since its inception in 2018, the company has set up a complete quality management system and is now ISO :13485 :2016 certified, with a suite of products available on the European market.For more information, please visit http://www.braintale.fr

View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005591/en/

Excerpt from:
Braintale Appoints Industry Leaders Spyros Artavanis-Tsakonas and Nitza Thomasson to Its Board of Directors - BioSpace

Cell Biology

Cloud Computing in Cell Biology, Genomics and Drug Development Market Global Demand, Research and Top Leading Player to 2026 Covid-19 Analysis KSU |…

Cloud Computing in Cell Biology, Genomics Drug Development Market Report defines the business objective to help business owners to avoid contradictory expectations. It provides you customer data along with their demands hence you can accordingly plan for the launching of the product in the market. It presents all the data about whole market scenario. With the help of prominent data provided in the Cloud Computing in Cell Biology, Genomics Drug Development Market Report, organizations come to know about customers completely and can achieve their goal of selling products in huge quantity and getting huge profits too. Clearly setting the business goal at the beginning will surely help to avoid getting difficulties and set the business easily.

Request sample copy of this report at

https://www.researchforetell.com/reports/68629/cloud-computing-in-cell-biology-genomics-and-drug-development-marketglobal-outlook-and-forecast-2021-2027/request

The scope of this research report extends from the basic outline of the Cloud Computing in Cell Biology, Genomics Drug Development Market to tricky structures, classifications and applications. This research report also provides a clear picture of the global market by presenting data through effective information graphics. It also provides a detailed list of factors that affect market growth.

A detailed study of the competitive landscape of the Global Cloud Computing in Cell Biology, Genomics Drug Development Market has been given along with the insights of the companies, financial status, trending developments, mergers & acquisitions and SWOT analysis. This research will give a clear and precise idea about the overall market to the readers to take beneficial decisions.

Cloud Computing in Cell Biology, Genomics Drug Development Market Report provides future growth drivers and competitive landscape. This will be beneficial for buyers of the market report to gain a clear view of the important growth and subsequent market strategy. The granular information in the market will help monitor future profitability and make important decisions for growth.

Inquire for a discount at

https://www.researchforetell.com/reports/68629/cloud-computing-in-cell-biology-genomics-and-drug-development-marketglobal-outlook-and-forecast-2021-2027/discount

This report contains market size and forecasts of Cloud Computing in Cell Biology, Genomics and Drug Development in Global, including the following market information:

Global Cloud Computing in Cell Biology, Genomics and Drug Development Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global top five companies in 2020 (%)

The global Cloud Computing in Cell Biology, Genomics and Drug Development market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cloud Computing in Cell Biology, Genomics and Drug Development companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Cloud Computing in Cell Biology, Genomics and Drug Development Market, By Type, 2016-2021, 2022-2027 ($ millions)

Global Cloud Computing in Cell Biology, Genomics and Drug Development Market Segment Percentages, By Type, 2020 (%)

Public Cloud

Private Cloud

Hybrid Cloud

China Cloud Computing in Cell Biology, Genomics and Drug Development Market, By Application, 2016-2021, 2022-2027 ($ millions)

China Cloud Computing in Cell Biology, Genomics and Drug Development Market Segment Percentages, By Application, 2020 (%)

Pharmaceutical and Biotechnology Companies

Contract Research Organizations (CROs)

Clinical Laboratories

Hospitals and Research Institutes

Others

Global Cloud Computing in Cell Biology, Genomics and Drug Development Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)

Global Cloud Computing in Cell Biology, Genomics and Drug Development Market Segment Percentages, By Region and Country, 2020 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Total Cloud Computing in Cell Biology, Genomics and Drug Development Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)

Total Cloud Computing in Cell Biology, Genomics and Drug Development Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:

Google Inc.

Amazon Web Services, Inc.

IBM Corp.

Oracle Corporation

Microsoft Corp.

Arisglobal

Benchling

Box Inc

Cisco Systems

Dell Emc

Cognizant

Dincloud

Exponential-e

Informatica

Key Features of the Report:

Complete report is available at

https://www.researchforetell.com/reports/68629/cloud-computing-in-cell-biology-genomics-and-drug-development-marketglobal-outlook-and-forecast-2021-2027

There are 10 Chapters to deeply display the Cloud Computing in Cell Biology, Genomics Drug Development Market.

Chapter 1 to analyze the top manufacturers of Cloud Computing in Cell Biology, Genomics Drug Development, with sales, revenue and price of Cloud Computing in Cell Biology, Genomics Drug Development in 2021-2027.

Chapter 2, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2021-2027.

Chapter 3, to show the global market by regions, with sales, revenue and market share of Cloud Computing in Cell Biology, Genomics Drug Development, for each region, from 2021-2027.

Chapter 4, 5, 6 and 7 to analyze the key regions, with sales, revenue and market share by key countries in these regions.

Chapter 8 and 9, to show the market by type and application, with sales market share and growth rate by type, application, from 2021-2027.

Chapter 10 Cloud Computing in Cell Biology, Genomics Drug Development Market forecast, by regions, type and application, with sales and revenue, from 2021-2027.

About Us

Research Foretell is an information service company that provides market research, custom, and consulting services. Decision-making is complicated and we help you to solve your biggest puzzle, by identifying, analyzing, and monitoring the recent developing technologies and markets. Research Foretell is always forefront on classifying new opportunity in the market; with us you always have the first mover advantage.

Contact Us:

Robert Claussen (Head of Sales)

Phone: +91-81499-24059

Email: sales@researchforetell.com

The rest is here:
Cloud Computing in Cell Biology, Genomics and Drug Development Market Global Demand, Research and Top Leading Player to 2026 Covid-19 Analysis KSU |...

Cell Biology

Global Cloud Computing in Cell Biology, Genomics and Drug Development Market 2021 Briefing, Trends, Applications, Types, Research, Forecast To 2026 …

Global Cloud Computing in Cell Biology, Genomics and Drug Development Market 2021 by Company, Regions, Type and Application, Forecast to 2026 presents a meticulous investigation of the current scenario of the market that contains wide-ranging industry information. The report throws light on dedicated references and the strategic functionality of various global market elements. The report explores practical growth strategies and recommendations related to the global Cloud Computing in Cell Biology, Genomics and Drug Development industry. It also contains helpful and important facts and figures, expert opinions, and the latest developments across the globe. To calculate the global market size, the report considers the revenue generated from the sales of Cloud Computing in Cell Biology, Genomics and Drug Development globally.

The report helps readers gauge future-specific growth probabilities, along with a thorough evaluation of primary growth initiators and focused elements that augment growth revenue generation, aligning with appropriate growth objectives. It highlights exclusive and relevant factors related to this market. Key players in global and major regions are assessed and the market is classified by product and application/end industries. The report throws light on multiple sections of the report including the global Cloud Computing in Cell Biology, Genomics and Drug Development market size and forecast, drivers, challenges, trends, and more.

NOTE: COVID-19 has had a major impact on the world economy in addition to that on the public health. This particular pandemic had caused severe economic destruction and not a single country has been left unaffected. The virus has forced businesses around the globe to change the way they operate. This report gives an analysis of the COVID-19 aftermath on Cloud Computing in Cell Biology, Genomics and Drug Development market.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/187077

In this comprehensive report, the competitive landscape is analyzed in terms of markets, applications, and geographies. The competitive analysis helps the vendors know their capabilities and opportunities for future growth prospects. The report then incorporates a thorough assessment of market participation showcased by inquisitive market players, followed by an assessment of their overall footing in the competitive landscape. The global Cloud Computing in Cell Biology, Genomics and Drug Development industry size is defined and forecasted with respect to type, application, and region.

The top players listed in the market report are:

Based on type, the report split into:

Based on application market is segmented into:

Market segmentation, by regions:

Important Figures Measured In This Report:

The report incorporates financial implications of various developments comprising production and consumption patterns. Expert research opinion also ensures that the growth delay is a significant concern which is further believed to demonstrate suitable indication in the upcoming times as well. Moreover, vendors successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies are highlighted in the global Cloud Computing in Cell Biology, Genomics and Drug Development report to help them execute further business expansion and growth.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/187077/global-cloud-computing-in-cell-biology-genomics-and-drug-development-market-2021-by-company-regions-type-and-application-forecast-to-2026

Highlights of The Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

Read more:
Global Cloud Computing in Cell Biology, Genomics and Drug Development Market 2021 Briefing, Trends, Applications, Types, Research, Forecast To 2026 ...

Cell Biology

Novo Nordisk partners with Heartseed on heart failure cell therapy – PMLiVE

Danish pharma company Novo Nordisk has announced a new collaboration and licence agreement with Japans Heartseed to develop the companys investigational cell therapy HS-001 for heart failure.

HS-001, Heartseeds lead asset, is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC). The therapy is currently being developed as a treatment for heart failure.

Heartseed is already planning to launch a phase 1/2 study of HS-001 in Japan in the second half of 2021, which will evaluate the safety and efficacy of the therapy for the treatment of heart failure caused by ischaemic heart disease.

Under the terms of their agreement, Novo Nordisk will gain exclusive rights to develop, manufacture and commercialise HS-001 globally, excluding Japan where Heartseed will retain the rights to solely develop the therapy.

However, Novo Nordisk has the rights to co-commercialise HS-001 with Heartseed in Japan, with equal profit and cost sharing.

In return, Heartseed is eligible to receive up to a total $598m, with $55m earmarked in upfront and near-term milestone payments.

The Japanese biotech company is also eligible to receive tiered high single-digit to low double-digit royalties of annual net sales on the product outside Japan.

"We are delighted to have a company with the expertise and resources of Novo Nordisk as our partner for development and commercialisation of HS-001, and are also honoured that Novo Nordisk has recognised the innovativeness and high potential of our technology," said Keiichi Fukuda, chief executive officer of Heartseed.

"We believe that the partnership with Novo Nordisk is very valuable as we seek to disseminate our Japan-origin innovation globally as early as possible, he added.

Through this important collaboration with Heartseed, we aim to pioneer novel treatment solutions for people with cardiovascular disease, said Marcus Schindler, chief scientific officer, EVP research and early development at Novo Nordisk.

We [will] gain access to an innovative clinical asset, underlying technology and deep expertise within the field of iPSC biology and cardiac cell transplantation, which can be combined with our knowledge and capabilities in stem cell biology and manufacturing, he added.

Read the original here:
Novo Nordisk partners with Heartseed on heart failure cell therapy - PMLiVE

Cell Biology

Global Cell Biology Test Kits Market 2021 In-Depth Growth Analysis of Key Industry Companies | Thermo Fisher Scientific, Bio-Rad, Promocell, Merck,…

Latest Market Research Report on Global Cell Biology Test Kits Market with focus on Industry Analysis, Regional Forecasts, Market Trends, Post Lockdown Market Growth & Opportunities, Rcent Developments, Market Applications & Solutions, Worldwide Investments, Upcoming Challenges and Profiles of Key Business Players by 2025.

Market research reports are considered an integral part for many business organizations as it provides them with the much needed information to proliferate their business reach within the market. These high-profile and concise reports shed light on the current market facts and figures, its growth projections, future development prospects and also help delineate competitor analysis and customer behavior. The global Cell Biology Test Kits market is known to be one of the top markets across the world. The Cell Biology Test Kits market is also globally recognized for its super productive and ever-efficient functioning. From their detailed qualitative and quantitative research to accurate SWOT and PEST analysis, this market research reports provide great knowledge on how to go about using different strategies to open up opportunities in a diverse market.

This research report contains through information on all the key parameters of the global Cell Biology Test Kits market. This report contains key information such as facts and figures, market research, market analysis, market shares, growth status, developments, opportunities, regional investments and much more. The report also contains qualitative and quantitative research which gives you a detailed overview of the present status of global Cell Biology Test Kits market. The report is perfect as you will get important information on the market scenario, based on which you can make business decisions in the Cell Biology Test Kits industry.

Post-Lockdown Market Scenario

Talking about diverse markets, we all know the impact COVID-19 has had on the global Cell Biology Test Kits market. It certainly changed the economic landscape of the global industry and every business had to go through the struggle of adjusting to alternatives. As markets around them battled with the repercussions of the virus, the global Cell Biology Test Kits market continued to generate the desired revenue and business investments. The Cell Biology Test Kits market was able to sway through all these challenges with the help of well adaptive and flexible business strategies and the vital and timely investments by their key companies.

Market Key Players

Key players are the all-important movers & shakers of any industry. Knowing the right key players with their share in the market provides you an upper hand over your peers. And this is where this research report becomes handy for you. With a charted list of key players and companies, their size and shares in the Cell Biology Test Kits market, and a well-summarized risk analysis, the global Cell Biology Test Kits market is well-equipped to push through its goals even when the market seems to be slowing down. All of their information and data are collected through primary and various secondary mediums via newsletters, annual reports, or surveys and assessed, graphs etc.

Get The Sample Report PDF with TOC & List of Figures @ https://marketresearchport.com/request-sample/154658

Leading Companies Covered in this Research Report:

Thermo Fisher Scientific, Bio-Rad, Promocell, Merck, Universal Biologicals, Perkinelmer

This Research Report is further divided into the Following Segments:

Market Segmentation by Product Types:Bacteria Test Kits, Protein Test Kits

Market Segmentation by Applications:Pharmaceutical, Research Institutes

Leading Regions covered in the Global Cell Biology Test Kits Market:

North America (United States, Canada) South America Europe (Germany, UK, France, Italy) Asia-Pacific (China, Japan, India, Korea) Rest of the World (Middle East, Africa, GCC)

FAQs Answered in this Research Report:

What is the estimated CAGR of the Global Cell Biology Test Kits market?What will be the global value of the Cell Biology Test Kits market by the year 2026?Which companies will dominate the global Cell Biology Test Kits market in 2021?Which regions will dominate the Cell Biology Test Kits market in 2021?What are the upcoming challenges and opportunities in the Cell Biology Test Kits market?Which global regions are expecting the consistent growth?Which key trends and industry applications will dictate the Cell Biology Test Kits market?Which business strategies will help sustain rapid and consistent growth in the Cell Biology Test Kits market?What will be an important area of focus for business investors and stakeholders in the Cell Biology Test Kits market?

This research report on the Cell Biology Test Kits market is a high-quality report prepared by the best minds in the market research industry. Every person involved in the research and writing of the report is an expert with excellent credentials and respectable experience in the Cell Biology Test Kits market. They have been a part of the research industry since a long time and have closely studied the Cell Biology Test Kits market to bring you data thats accurate and trustworthy. The data in this research report is represented in a visual and textual format. You can use both forms of data representations for your interpretation.

Explore Complete Report on Global Cell Biology Test Kits Market @ https://marketresearchport.com/reports/global-cell-biology-test-kits-market-report-2021/154658

Important Chapters From The Table of Content (TOC) :

Section 1 Cell Biology Test Kits Product Definition

Section 2 Global Cell Biology Test Kits Market Manufacturer Share and Market Overview2.1 Global Manufacturer Cell Biology Test Kits Shipments2.2 Global Manufacturer Cell Biology Test Kits Business Revenue2.3 Global Cell Biology Test Kits Market Overview2.4 COVID-19 Impact on Cell Biology Test Kits Industry

Section 3 Manufacturer Cell Biology Test Kits Business Introduction3.1 Thermo Fisher Scientific Cell Biology Test Kits Business Introduction3.1.1 Thermo Fisher Scientific Cell Biology Test Kits Shipments, Price, Revenue and Gross profit 2015-20203.1.2 Thermo Fisher Scientific Cell Biology Test Kits Business Distribution by Region3.1.3 Thermo Fisher Scientific Interview Record3.1.4 Thermo Fisher Scientific Cell Biology Test Kits Business Profile3.1.5 Thermo Fisher Scientific Cell Biology Test Kits Product Specification

3.2 Bio-Rad Cell Biology Test Kits Business Introduction3.2.1 Bio-Rad Cell Biology Test Kits Shipments, Price, Revenue and Gross profit 2015-20203.2.2 Bio-Rad Cell Biology Test Kits Business Distribution by Region3.2.3 Interview Record3.2.4 Bio-Rad Cell Biology Test Kits Business Overview3.2.5 Bio-Rad Cell Biology Test Kits Product Specification

3.3 PromoCell Cell Biology Test Kits Business Introduction3.3.1 PromoCell Cell Biology Test Kits Shipments, Price, Revenue and Gross profit 2015-20203.3.2 PromoCell Cell Biology Test Kits Business Distribution by Region3.3.3 Interview Record3.3.4 PromoCell Cell Biology Test Kits Business Overview3.3.5 PromoCell Cell Biology Test Kits Product Specification3.4 Merck Cell Biology Test Kits Business Introduction3.5 Universal Biologicals Cell Biology Test Kits Business Introduction3.6 PerkinElmer Cell Biology Test Kits Business Introduction

Section 4 Global Cell Biology Test Kits Market Segmentation (Region Level)4.1 North America Country4.1.1 United States Cell Biology Test Kits Market Size and Price Analysis 2015-20204.1.2 Canada Cell Biology Test Kits Market Size and Price Analysis 2015-20204.2 South America Country4.2.1 South America Cell Biology Test Kits Market Size and Price Analysis 2015-20204.3 Asia Country4.3.1 China Cell Biology Test Kits Market Size and Price Analysis 2015-20204.3.2 Japan Cell Biology Test Kits Market Size and Price Analysis 2015-20204.3.3 India Cell Biology Test Kits Market Size and Price Analysis 2015-20204.3.4 Korea Cell Biology Test Kits Market Size and Price Analysis 2015-20204.4 Europe Country4.4.1 Germany Cell Biology Test Kits Market Size and Price Analysis 2015-20204.4.2 UK Cell Biology Test Kits Market Size and Price Analysis 2015-20204.4.3 France Cell Biology Test Kits Market Size and Price Analysis 2015-20204.4.4 Italy Cell Biology Test Kits Market Size and Price Analysis 2015-20204.4.5 Europe Cell Biology Test Kits Market Size and Price Analysis 2015-20204.5 Other Country and Region4.5.1 Middle East Cell Biology Test Kits Market Size and Price Analysis 2015-20204.5.2 Africa Cell Biology Test Kits Market Size and Price Analysis 2015-20204.5.3 GCC Cell Biology Test Kits Market Size and Price Analysis 2015-20204.6 Global Cell Biology Test Kits Market Segmentation (Region Level) Analysis 2015-20204.7 Global Cell Biology Test Kits Market Segmentation (Region Level) Analysis

Section 5 Global Cell Biology Test Kits Market Segmentation (Product Type Level)5.1 Global Cell Biology Test Kits Market Segmentation (Product Type Level) Market Size 2015-20205.2 Different Cell Biology Test Kits Product Type Price 2015-20205.3 Global Cell Biology Test Kits Market Segmentation (Product Type Level) Analysis

Section 6 Global Cell Biology Test Kits Market Segmentation (Industry Level)6.1 Global Cell Biology Test Kits Market Segmentation (Industry Level) Market Size 2015-20206.2 Different Industry Price 2015-20206.3 Global Cell Biology Test Kits Market Segmentation (Industry Level) Analysis

Section 7 Global Cell Biology Test Kits Market Segmentation (Channel Level)7.1 Global Cell Biology Test Kits Market Segmentation (Channel Level) Sales Volume and Share 2015-20207.2 Global Cell Biology Test Kits Market Segmentation (Channel Level) Analysis

Section 8 Cell Biology Test Kits Market Forecast 2020-20258.1 Cell Biology Test Kits Segmentation Market Forecast (Region Level)8.2 Cell Biology Test Kits Segmentation Market Forecast (Product Type Level)8.3 Cell Biology Test Kits Segmentation Market Forecast (Industry Level)8.4 Cell Biology Test Kits Segmentation Market Forecast (Channel Level)

Section 9 Cell Biology Test Kits Segmentation Product Type9.1 Bacteria Test Kits Product Introduction9.2 Protein Test Kits Product Introduction

Section 10 Cell Biology Test Kits Segmentation Industry10.1 Pharmaceutical Clients10.2 Research Institutes Clients10.3 Biotech Laboratories Clients

Section 11 Cell Biology Test Kits Cost of Production Analysis11.1 Raw Material Cost Analysis11.2 Technology Cost Analysis11.3 Labor Cost Analysis11.4 Cost Overview

Section 12 Conclusion

REPORT CUSTOMIZATION: Although Market Research Port has tried its best to cover every minor and major detail in the Cell Biology Test Kits market research report, we still believe that every business investor or an industry user may have their own specific requirements. Keeping this in mind, we will provide customization on this report and cover your additional or extra requirements in the report.

About Us:Market Research Port is one of the best report reseller company in the market bringing to you accurate and trustworthy market research reports by reputed publishers. Our trusted publishers have compiled their reports and findings after painstaking research and studies, set up against varied business parameters. Each report is detailed and then vetted for accuracy by industry experts. In each report, you will find deep analysis, risk analysis, market forecasts, emerging trends, different market segments, technological advancement and its impact, and a multitude of economic factors, giving you the most comprehensive market research reports.

Contact Us:Market Research Port,Brighton Street, Providence,Rhode Island 02929, United StatesContact No: +1 401 433 7610Email: [emailprotected]Website: https://marketresearchport.com/

Read the original:
Global Cell Biology Test Kits Market 2021 In-Depth Growth Analysis of Key Industry Companies | Thermo Fisher Scientific, Bio-Rad, Promocell, Merck,...

Cell Biology

Cell Expansion Market demand with COVID-19 recovery analysis 2021 | better delivery process to boost market growth by 2027 The Manomet Current – The…

Global Cell Expansion Market is valued approximately USD 12.9 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 15.1 % over the forecast period 2020-2027.

Cell expansion processes for clinical use require special considerations such as product safety and control for cell function. cell expansion is also used to improve transplantation and in the treatment of various diseases such as diabetes, rheumatoid arthritis and others. Cell based approaches are highly demanded during COVID-19 as this therapy reduces the expression of pro-inflammatory cytokines as well as repair of damaged tissues in COVID-19 patients. Thus cell expansion market is highly demanded across the world during coronavirus pandemic. The increasing incidence of chronic diseases, government investments for cell-based research, growing focus on personalized medicine, rising focus on R&D for cell-based therapies and growing Good manufacturing practice (GMP) certifications for cell therapy production facilities are the few factors responsible for growth of the market over the forecast period.

Request for a FREE sample of this market research report@ https://www.reportocean.com/industry-verticals/sample-request?report_id=bw1330

Furthermore, the rising advancements and other strategic alliance by market key players will create a lucrative demand for this market. For instance: on 05th November 2019, Thermo Fisher Scientific, Inc. Invested around USD 24 million for the expansion of its ability to manufacture cell culture media at Inchinnan, Scotland. This investment will expand the capabilities and expertise companys existing cell culture manufacturing center of excellence in the UK . However, ethical concerns regarding research in cell biology is the major factor restraining the growth of global Cell Expansion market during the forecast period.

The regional analysis of global Cell Expansion market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world owing to the rising incidence of cancer, increasing government funding, rising research activates on stem cell therapies, growing awareness regarding advanced treatment methods, growing geriatric population, and the strong presence of industry players in the region. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2027.

Major market player included in this report are:Thermo Fisher Scientific, Inc.DanaherBecton, Dickinson And CompanyLonzaCorning IncorporatedMerck KgaaSartorius Stedim BiotechGetinge ABTerumo CorporationMiltenyi Biotec

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:ConsumablesInstrumentsBioreactorsAutomated Cell Expansion Systems

By Cell Type:Human CellsAnimal Cells

By Application:Regenerative Medicine and Stem Cell ResearchCancer and Cell-based ResearchOthers

By End Use:Research InstitutesBiotechnology and Biopharmaceutical CompaniesCell BanksOthers

By Region:North AmericaU.S.CanadaEuropeUKGermanyFranceSpainItalyROE

Asia PacificChinaIndiaJapanAustraliaSouth KoreaRoAPACLatin AmericaBrazilMexicoRest of the World

Furthermore, years considered for the study are as follows:

Historical year 2017, 2018Base year 2019Forecast period 2020 to 2027

Send a request to Report Ocean to understand the structure of the complete report @https://www.reportocean.com/industry-verticals/sample-request?report_id=bw1330

Target Audience of the Global Cell Expansion Market in Market Study:

Key Consulting Companies & AdvisorsLarge, medium-sized, and small enterprisesVenture capitalistsValue-Added Resellers (VARs)Third-party knowledge providersInvestment bankersInvestors

Read the rest here:
Cell Expansion Market demand with COVID-19 recovery analysis 2021 | better delivery process to boost market growth by 2027 The Manomet Current - The...

Cell Biology

Global Autoimmune Treatment Market Forecasts (2021-2028) with Industry Chain Structure, Competitive Landscape, New Projects and Investment Analysis …

Autoimmune diseases or disorders refers to the diseases that are caused due to damage to the healthy cells. The healthy cells get disrupted or get damages by the ones own immune system. The most commonly seen autoimmune diseases are rheumatoid arthritis, lupus, celiac disease, multiple sclerosis, type 1 diabetes and others. The treatment for these diseases include medication that suppress the immune system.

An exclusive Autoimmune Treatment Market research report has been fabricated through the in depth analysis of the market dynamics across five regions including North America, Europe, South America, Asia-Pacific, Middle East and Africa. The segmentation of the market by components, end users, and region was done based on the thorough market analysis and validation through extensive primary inputs from industry experts (key opinion leaders of companies, and stakeholders) and secondary research (global/regional associations, trade journals, technical white papers, companys website, annual report SEC filing, and paid databases). Further, the market has been estimated by utilizing various research methodologies and internal statistical model.

Get sample PDF copy @ https://www.theinsightpartners.com/sample/TIPRE00004203/

Bio-Autoimmune Treatment is an emerging field of research which deals with the aspects of both, biotechnology and nanotechnology. Precise patterning of biomolecules with the help of nanometer resolution can offer wide range of benefits in medical and biological applications such as molecular diagnostics, cell biology, and advanced medical diagnosis.

The research dives deep into the global share, size, and trends, as well as growth rate of the Autoimmune Treatment market to project its progress during the forecast period, i.e., 20202027. Most importantly, the report further identifies the past, present, and future trends that are expected to influence Autoimmune Treatment the development rate of the Autoimmune Treatment market. The research segments the market on the basis of product type, application, and region.

Autoimmune Treatment Market Key Player Analysis By

A detailed scrutiny of the regional terrain of the Autoimmune Treatment market:

The study broadly exemplifies, the regional hierarchy of this market, while categorizing the same into United States, China, Europe, Japan, Southeast Asia & India.

The research report documents data concerning the market share held by each nation, along with potential growth prospects based on the geographical analysis.

The study anticipates the growth rate which each regional segment would cover over the estimated timeframe.

Here we have listed the top Autoimmune Treatment Market companies in the world

Reasons for buying this report:

It offers an analysis of changing competitive scenario.

For making informed decisions in the businesses, it offers analytical data with strategic planning methodologies.

It offers a seven-year assessment of Autoimmune Treatment Market.

It helps in understanding the major key product segments.

Researchers throw light on the dynamics of the market such as drivers, restraints, trends, and opportunities.

It offers a regional analysis of Autoimmune Treatment Market along with business profiles of several stakeholders.

Chapter Details of Autoimmune Treatment Market:

Part 01: Executive Summary

Part 02: Scope of The Report

Part 03: Autoimmune Treatment Market Landscape

Part 04: Autoimmune Treatment Market Sizing

Part 05: Autoimmune Treatment Market Segmentation by Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers and Challenges

Buy a Complete Copy of this Report @ https://www.theinsightpartners.com/buy/TIPRE00004203/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

Call: +1-646-491-9876

Email: sales@theinsightpartners.com

See the original post:
Global Autoimmune Treatment Market Forecasts (2021-2028) with Industry Chain Structure, Competitive Landscape, New Projects and Investment Analysis ...

Cell Biology

Akoya and AstraZeneca to Collaborate on Spatial Biology Approach to Profiling Tumor-Immune Biology – GlobeNewswire

MARLBOROUGH, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA) The Spatial Biology Company, today announced a collaboration with AstraZeneca to advance new multiplex immunofluorescence (mIF) workflows and spatial biomarker signatures, based on Akoyas Phenoptics platform. The agreement between one of the worlds leading pharmaceutical companies and a top innovator in spatial biology technologies has the aim of elucidating the immune biology of cancer, in greater detail, to streamline drug development, clinical trials, and biomarker discovery.

Immunotherapies, a rapidly growing treatment modality, utilize the immune system to combat cancer and are revolutionizing the field of oncology. While they have shown tremendous promise, only a subset of patients achieves durable response, impacting drug efficacy rates and approvals. There is a pressing need for predictive biomarkers that can accurately stratify responders from non-responders. However, identifying suitable biomarkers requires an in-depth understanding of tumor pathophysiology. A recent multi-institutional study of immuno-oncology biomarker modalities found that mIF-based spatial biomarkers have the potential to address this gap by analyzing the spatial architecture of tumor tissue sections, and mapping how tumor and immune cells organize and interact within the tumor microenvironment.1

With this collaboration, AstraZenecas immuno-oncology division will partner with Advanced Biopharma Solutions (ABS), a premium service offering from Akoya, to leverage the comprehensive spatial phenotyping capabilities of the Phenoptics platform to study drug mechanism of action, confirm target biology prevalence, and discover predictive signatures for subsequent trial designs. The aim of this collaboration will be the development and implementation of predictive assays and analysis frameworks to enable AstraZeneca, and the pharmaceutical industry in general, to advance a spatial biomarker-informed drug development strategy for immunotherapy. The results could lead to increased trial success rates and advancement of precision medicine.

We are very pleased to work with AstraZeneca and share their commitment in enabling next-generation innovations in the field of immuno-oncology, said Brian McKelligon, Chief Executive Officer of Akoya. The combination of AstraZenecas scientific leadership in immuno-oncology and Akoyas groundbreaking spatial biology capabilities promises to reshape the future of biomarker development and ultimately cancer care.

Akoyas ABS team will be exhibiting at the American Society for Clinical Oncology (ASCO) Virtual Meeting from June 4 to 8 at booth 5067a. To book a meeting, click here.

About Akoya Biosciences

As The Spatial Biology Company, Akoya Biosciences mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. To learn more about Akoya, visit http://www.akoyabio.com.

Cautionary Note Regarding Forward Looking StatementsThis press release contains forward-looking statements under applicable securities laws. In some cases, such statements can be identified by words such as: may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements regarding our ability to achieve our business strategies, growth, or other future events or conditions. Such statements are based on our current beliefs, expectations, and assumptions about future events or conditions, which are subject to inherent risks and uncertainties, including the risks and uncertainties discussed in the filings we make from time to time with the Securities and Exchange Commission. Actual results may differ materially from those indicated in forward-looking statements, and you should not place undue reliance on them. All statements herein are based only on information currently available to us and speak only as of the date hereof. Except as required by law, we undertake no obligation to update any such statement.

Investor Contact:David DeuchlerGilmartin Group LLCinvestors@akoyabio.com

Media Contact:

Michelle LinnBioscribe, Inc.774-696-3803 michelle@bioscribe.com

1 Lu S, Stein JE, Rimm DL, et al. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. JAMA Oncol. 2019

Originally posted here:
Akoya and AstraZeneca to Collaborate on Spatial Biology Approach to Profiling Tumor-Immune Biology - GlobeNewswire